ValuEngine lowered shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a sell rating in a research note published on Thursday morning.

Several other equities research analysts also recently issued reports on TBPH. BidaskClub upgraded shares of Theravance Biopharma from a strong sell rating to a sell rating in a research report on Saturday, January 20th. Leerink Swann raised their price objective on shares of Theravance Biopharma from $45.00 to $48.00 and gave the stock an outperform rating in a research report on Thursday, February 8th. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the stock a buy rating in a research report on Tuesday, February 27th. Finally, Piper Jaffray restated an overweight rating and set a $45.00 price objective on shares of Theravance Biopharma in a research report on Thursday, March 29th. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Theravance Biopharma has an average rating of Hold and a consensus price target of $42.43.

Shares of TBPH stock opened at $22.06 on Thursday. The company has a debt-to-equity ratio of 1.94, a current ratio of 6.05 and a quick ratio of 5.79. The company has a market cap of $1,215.40, a price-to-earnings ratio of -4.05 and a beta of 1.81. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.15) by ($0.49). The company had revenue of $4.52 million for the quarter, compared to analyst estimates of $3.71 million. Theravance Biopharma had a negative return on equity of 136.86% and a negative net margin of 1,855.42%. sell-side analysts anticipate that Theravance Biopharma will post -4.61 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Deutsche Bank AG raised its position in shares of Theravance Biopharma by 82.4% in the fourth quarter. Deutsche Bank AG now owns 108,750 shares of the biopharmaceutical company’s stock valued at $3,031,000 after buying an additional 49,137 shares in the last quarter. Woodford Investment Management Ltd raised its position in shares of Theravance Biopharma by 0.4% in the fourth quarter. Woodford Investment Management Ltd now owns 10,747,108 shares of the biopharmaceutical company’s stock valued at $227,270,000 after buying an additional 41,000 shares in the last quarter. Virtus Fund Advisers LLC acquired a new stake in shares of Theravance Biopharma in the fourth quarter valued at approximately $974,000. Wells Fargo & Company MN raised its position in shares of Theravance Biopharma by 32.0% in the third quarter. Wells Fargo & Company MN now owns 117,079 shares of the biopharmaceutical company’s stock valued at $4,009,000 after buying an additional 28,391 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Theravance Biopharma in the fourth quarter valued at approximately $419,000. Institutional investors own 85.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/04/22/theravance-biopharma-tbph-cut-to-sell-at-valuengine.html.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.